Cancer deaths usually result from the development of metastasis and the lack of curative approaches, at least for the most frequent tumour localisations. At this latter stage of the disease, cancer chemotherapy remains the most powerful and often the only available therapeutic approach.
‍
However, chemotherapy is not entirely effective against many solid tumours’ types. 
‍
Most anticancer drugs lack any intrinsic antitumor selectivity. In turn, chemotherapy is frequently associated with severe side effects due to the destruction of normal tissues. As a result, the quantity of drugs that can be administered is usually insufficient to deliver an efficient concentration of the anticancer agent at the tumour site. 

The Antibody Drug Conjugates (ADC) is facing also limitations in its activity

Moreover, the lack of selectivity of current anticancer drugs dramatically increases the risk of development of cellular resistance by tumours cells.

‍Hence, there is a need to develop more a selective and targeted approach for solid tumours.

0

Million deaths in the world
due to cancer

0

New cancer cases are diagnosed
each day worldwide

0

% of all cancers diagnosed
are solid tumors (lung,
breast, pancreas...)

0

% of all deaths are due to solid
tumors (lung, breast, pancreas...)

An urgent need for better treatments for solid tumors

Over the past decade, scientists have been working on finding ways to specifically target solid tumors in order to reduce adverse effects and to increase treatment efficacy.

Seekyo has developed a disruptive new generation of targeted therapy: Tumor Activated Therapy  

Smart Chemotherapy

A double targeting of the Tumor Micro-Environment

SKY01

We developed SKY01, a selective anticancer agent possessing a unique mode of action resulting from the combination of the subsequent steps:

Those steps are expected to occur independently of the tumor type, allowing for the therapy of many solid tumors.

Based on Seekyo’s innovative molecular platform SKY^TM, we have successfully tested several combinations of active agents (cytotoxic drugs, immune-stimulants….), targeting units and cleavable linkers adapted at targeting the TME.
In addition to generating promising internal leads (eg. SKY02 – immuno-stimulant) the platform has the potential to optimize existing drugs (e.g. widening the therapeutic window) for industrial partners.